Peripheral neuropathies associated with immunoglobulin M monoclonal gammopathies and low-grade B-cell lymphomas: diagnostic and therapeutic approach.
Newer targeted treatments for rare nerve damage from blood cancers offer real promise, though more rigorous testing is still needed.
IgM monoclonal gammopathy-associated peripheral neuropathies (predominantly anti-MAG neuropathy) are increasingly managed with clone-directed approaches (anti-CD20 and cBTKi), but high-quality RCT evidence remains limited; many patients experience persistent disability despite treatment. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Narrative review
- Category
- hematologic_malignancies
- Maturity
- Exploratory
Why it surfaced
Clinically relevant update on a diagnostic and therapeutic challenge at the intersection of hematology and neurology; timely for practices managing WM/IgM MGUS with neuropathy. Published in Current Opinion in Oncology by a Pitié-Salpêtrière expert.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.